Navigation Links
Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
Date:10/29/2008

rally well tolerated. The most frequently reported adverse events for patients taking VYVANSE were decreased appetite, insomnia, headache, irritability, upper abdominal pain, and affect lability.

VYVANSE, which was introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years, was approved in April 2008 to treat ADHD in adults. VYVANSE is now available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. To date, more than 3 million VYVANSE prescriptions have been filled.

VYVANSE is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of VYVANSE to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times.

Additional information about VYVANSE and Full Prescribing Information are available at http://www.vyvanse.com.

Notes to Editor:

The Swanson, Kotkin, Agler, M-Flynn, and Pelham Deportment (SKAMP-D) scale is a standardized, validated classroom assessment tool used for evaluating the behavioral symptoms of ADHD and higher SKAMP-D ratings reflecting greater impairment.

The Permanent Product Measure of Performance (PERMP) is an age-adjusted collection of math problems that provides an objective measure of performance based on the number of attempted and completed math problems.

About VYVANSE

Vyvanse is indicated for the treatment of ADHD. Efficacy based on two controlled trials in children aged 6 to 12 and one controlled trial in adults.

Tell the doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform the doctor immediately if you or your child develops symptoms that suggest heart problems, such as chest pain or fainting.

Vyvanse should not be
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
2. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
3. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
4. Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients
5. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
6. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
7. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
8. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
9. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
10. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
11. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014  AnaptysBio, Inc., a leader ... today announced the appointment of Marco Londei ... will lead the preclinical and clinical development of ... are pleased to welcome Dr. Londei to AnaptysBio,s ... President and Chief Executive Officer of AnaptysBio. "Dr. ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, received official notification from ... been granted another key patent supporting its iSONEP™ ... issued patent, European patent No. 2087002, claims compositions ... in Lpath,s two lead compounds, iSONEP and ASONEP. ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... for Caring, is a 4-Star Sponsor of Operation ... Veterans with unique products, programs and services to assist ... freedom. Key Facts: , An ... is a safe and effective treatment for pain, Post-traumatic ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3
... and MONTREAL, Aug. 21 Pharmion,Corporation (Nasdaq: ... MYG), today announced that the U.S. Food and ... (HDAC) inhibitor,MGCD0103, as an Orphan Drug for the ... for designation require that the product be,intended for ...
... Aug. 21 Advanced Life Sciences,Holdings, Inc. ... commencement of its,collaboration with the National Institute ... governmental institute supporting biodefense,research, under which the ... Company,s late-stage antibiotic, as a treatment for,anthrax ...
Cached Medicine Technology:Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma 2Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma 3Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma 4Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today ... new module enables easy administration and routing of follow-up ... , This application allows users such as Therapists to ... to-do item to a specific client, categorize tasks the ... reminders for follow-ups. It's designed to enable easy ...
(Date:10/20/2014)... Myoderm announced today ... of their CentralSource service. Matthew will ... turnkey drug sourcing, distribution, and management service for ... years of industry experience, in both business development ... of their international success to help clients manage ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... NORTH HOLLYWOOD, Calif., Nov. 18 IPC The Hospitalist Company ... Hospital Internists of New London (HINL), based in New London, ... Rhode Island. The acquisition of these two practices marks IPC,s ... 21 states. The two practices combined have approximately 55,000 patient ...
... ... information, not friendly one-on-one conversation. , ... New York, NY (PRWEB) November 18, 2009 -- A new ... older e-patients to “friend” them on Facebook. Instead, health organizations would be better ...
... other women , WEDNESDAY, Nov. 18 (HealthDay News) -- New ... slightly higher risk for giving birth via cesarean deliveries or ... womb. , But the researchers, whose findings were published ... pregnant women with MS were not more likely than other ...
... Young football players may ... series of even small head bumps may be at increased risk of long-term brain damage., ... Boston (Vocus) November 19, 2009 -- Young ... who sustain a series of even small head bumps may be at increased risk of long-term ...
... High-Tech Institute in Minneapolis will begin offering six new degree ... for all programs. The school is located at 5100 ... , High-Tech Institute Minneapolis will offer six new Associate of ... Coding, Massage Therapy, Pharmacy Technician, Surgical Technologist and Limited Scope ...
... anti-clotting alternatives , WEDNESDAY, Nov. 18 (HealthDay News) -- ... that the latest generation of blood thinners may outperform ... one study, dabigatran etexilate (marketed as Pradax in Canada ... in the United States) proved to be safe in ...
Cached Medicine News:Health News:IPC The Hospitalist Company Acquires Two New England Practices 2Health News:Older E-Patients Prefer Facts, Not Friendship from Health Organizations Communicating Via Social Media, According to Path of the Blue Eye Project Survey 2Health News:MS Need Not Preclude Pregnancy 2Health News:Throw a Yellow Flag on Football-related Head Injuries, Warns the Harvard Mental Health Letter 2Health News:High-Tech Institute Minneapolis to Offer Six New Associate of Science Degree Programs 2Health News:High-Tech Institute Minneapolis to Offer Six New Associate of Science Degree Programs 3Health News:Newer Blood Thinners May Outperform Old Standbys 2Health News:Newer Blood Thinners May Outperform Old Standbys 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: